(Adnkronos) - “Uniformare l’approccio ai soggetti con emicrania in tutto il mondo, non solo in Italia” come evidenziano “una serie di linee guida” parallele alle “linee guida europee. Tutti i farmaci che hanno dimostrato di avere efficacia nell'emicrania sono stati analizzati da un punto di vista metodologico solido. Sarà” infatti “disponibile un elenco che affiancherà le linee guida”. Lo ha detto Cristina Tassorelli, professore di Neurologia e presidente Facoltà di Medicina e Chirurgia università di Pavia, in occasione dell’evento ‘Empatia, empowerment, emicrania: vivere la vita’, organizzato a Roma da Organon Italia e dedicato alle nuove terapie per l’emicrania.
Category
🗞
NewsTranscript
00:00What do you think about the approach to hemicrania?
00:04As far as the approach to hemicrania is concerned, there are many novelties.
00:09These novelties have been included in a series of guidelines.
00:14There are European guidelines.
00:16International guidelines are now being published,
00:20which are actually Italian and international.
00:23We will have a list of drugs with comments from experts
00:27that go alongside the other guidelines.
00:30The main intention is to unify as much as possible
00:35the approach to subjects with hemicrania around the world.
00:39Not only in Italy, not only in different countries.
00:42We have many drugs and our idea would be
00:45to make these drugs available to all people who suffer from this disease.
00:50Because it is disabling, because these drugs are effective,
00:54because especially the new ones are very well tolerated,
00:57so they don't need monitoring, they don't create toxicity.
01:01This was the first step.
01:03The second step is to decline the effectiveness of drugs
01:08into practical recommendations.
01:10We have done this on two levels.
01:12The level at which the doctor has all the drugs available for treatment
01:19and the level, let's say, in poorer countries,
01:22where only a few of these drugs are available.
01:25In any case, there is the possibility of making patients feel better.
01:28So we gave the recommendations for both levels.
01:31Then we did something else.
01:33We asked the World Health Organization
01:36to increase the number of drugs included in the list of essential drugs,
01:42those that should be available all over the world,
01:45to increase this list by adding more drugs,
01:48including some of these new drugs.
01:51Because really, in that list there were very few drugs for migraines.
01:55We did something else recently.
01:57That was also an Italian idea.
01:59We proposed to change what we want to obtain for our patients with migraines.
02:04While until yesterday we said,
02:06effective drugs, what reduces the 50% of migraine days per month,
02:11which is a good value,
02:13but if we think that a patient with chronic migraine has 30 days per month,
02:17if we remove 15 days, there are 15 days left.
02:20So we asked ourselves, is this enough? No.
02:22So we made some other goals that we want to target.
02:27It is not said that we will reach them.
02:30Certainly we will not reach them for all people.
02:33But the first goal, the optimum, is migraine freedom.
02:38Freedom from migraines for a month, two months, three months, as long as possible.
02:42So no migraines.
02:43As soon as we reach the bottom, the optimum.
02:46Control of the disease.
02:48So the optimal control of the disease,
02:50which means no more than four days per month of migraines
02:53or severe moderate-intensity cephalitis.
02:55And in these four days that there are,
02:58have a good symptomatic drug that controls the attacks that escape.
03:02So it's a bit of a change of perspective.
03:05In our opinion, with the drugs we have available,
03:07with the ongoing research,
03:09there will be other drugs available,
03:12for those who treat patients with migraines,
03:14but especially for patients.